Biomarkers refer to genes, molecules or certain characteristics enabling to evaluate or measure pharmacologic response to therapeutic treatment, or various pathogenic or biological processes. Categorized by their utilization in different medical procedures, biomarkers facilitate decision-taking in early clinical drug development, thus helping to detect a patient’s health state. Oncology belongs within the major diseases where biomarkers are widely used.
Supported by novel product’s introductions, fresh market entrants, as well as M&As and other related activities, the world Biomarkers Market is evolving at a colossal tempo, set to be ultimately valued at just over EUR 26 billion by end-2018. Novel technologies exploited for biomarker discovery are the foremost contributors to the Biomarkers sector. North America heads the market as the most speedily growing geographic area. Major Biomarkers Market participants encompass, among others, Abbot Laboratories, Affymetrix, Agilent, Epigenomics, Celera, GE Healthcare, and DiagnoCure.
The research reports under this MarketPublishers’ Catalogue delve deep into the Biomarkers Market and its major submarkets – discovery technologies, services market, application market, and various indications. Covering various geographies, the research reports identify and examine the principal trends, opportunities, and the factors propelling or clogging the market growth. The competitive landscape with comprehensive profiles of numerous players in the global Biomarkers Industry, forecasts throwing light on the market’s future are provided in the research reports too.
Publications found:
2
Sort by:
